Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

Visualizza tutta la documentazione

Y0000366

Isradipine

European Pharmacopoeia (EP) Reference Standard

Sinonimo/i:

4-(4-Benzofurazanyl)-1,-4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid methyl 1-methylethyl ester

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali

Scegli un formato

125 MG
107,00 €

107,00 €

Per informazioni sulla disponibilità, contatta il Servizio Clienti.
Richiedi un ordine bulk
Tutte le immagini(1)

Scegli un formato

Cambia visualizzazione
125 MG
107,00 €

About This Item

Formula empirica (notazione di Hill):
C19H21N3O5
Numero CAS:
75695-93-1
Peso molecolare:
371.39
Numero MDL:
MFCD00153820
Codice UNSPSC:
41116107
ID PubChem:
329830922
NACRES:
NA.24

107,00 €

Per informazioni sulla disponibilità, contatta il Servizio Clienti.
Richiedi un ordine bulk

Grado

pharmaceutical primary standard

Famiglia di API

isradipine

Produttore/marchio commerciale

EDQM

applicazioni

pharmaceutical (small molecule)

Formato

neat

Temperatura di conservazione

2-8°C

Stringa SMILE

COC(=O)C1=C(C)NC(C)=C(C1c2cccc3nonc23)C(=O)OC(C)C

InChI

1S/C19H21N3O5/c1-9(2)26-19(24)15-11(4)20-10(3)14(18(23)25-5)16(15)12-7-6-8-13-17(12)22-27-21-13/h6-9,16,20H,1-5H3
HMJIYCCIJYRONP-UHFFFAOYSA-N

Informazioni sul gene

human ... CACNA1C(775) , CACNA1D(776) , CACNA1F(778) , CACNA1S(779)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Categorie correlate

Descrizione generale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Applicazioni

Isradipine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Azioni biochim/fisiol

L-type calcium channel blocker (also referred to as dihydropyridine-type calcium channel blocker); antihypertensive.
L-type calcium channel blocker; antihypertensive.

Confezionamento

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Altre note

Sales restrictions may apply.

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documenti section.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

J Marty
Acta anaesthesiologica Scandinavica. Supplementum, 99, 53-55 (1993-01-01)
The traditional therapy of perioperative hypertension is now being challenged by the availability of new agents. Vasodilator therapy should be the first-line choice, although dihydropyridine calcium antagonists, particularly isradipine, appear to be suitable in this setting because of their pharmacological
R P Hof et al.
American journal of hypertension, 4(2 Pt 2), 107S-113S (1991-02-01)
In the context of atherosclerosis, calcium antagonists should be evaluated from two points of view: their hemodynamic action on the atherosclerotic cardiovascular system, and their preventive action on atherosclerosis. Contraction of atherosclerotic vessels in response to vasoconstrictors, especially serotonin and
D Panuccio et al.
La Clinica terapeutica, 146(11), 729-736 (1995-11-01)
The aim of the present study was to evaluate efficacy on blood pressure values and metabolic tolerability of Isradipine, which was given to 15 mild hypertensive non diabetic subjects (average age 63.8 +/- 10.9 years), at the dosage of 5
W H Frishman
Journal of clinical pharmacology, 34(12), 1164-1172 (1994-12-01)
In the treatment of hypertension in renally impaired patients, normalization of blood pressure alone may not be sufficient to prevent significant morbidity to the kidneys. Treatment must reduce pressure in the renal vasculature, otherwise glomerular filtration rate and renal plasma
D Blecker
Angiology, 45(12), 997-1008 (1994-12-01)
Treatment of hypertension in the complicated patient requires a specialized approach focusing on the treatment of the blood pressure and concurrent medical problems. Therapy must be chosen in consideration of the patient's age, multiple illnesses, declining organ function, and possible
Visualizza tutti i documenti correlati

Domande

Recensioni

Nessuna valutazione

Filtri attivi

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.